West Nile Virus is a mosquito-borne pathogen with an expanding global footprint, capable of causing severe neuroinvasive disease including encephalitis and meningitis, particularly in the elderly and immunocompromised. With no specific vaccines or treatments available, early and accurate diagnosis is the primary clinical tool for guiding patient management and triggering public health responses. Traditional serological assays take 4 to 10 days and may lack sensitivity, while the gold-standard plaque reduction neutralization test is confined to specialized reference laboratories, creating a significant diagnostic gap in routine clinical settings.
The W. Nile-Q Real-Time PCR Kit from Genes2Me delivers sensitive, specific detection of WNV RNA in EDTA blood samples. Using a multiplex one-step RT-qPCR design with TaqMan chemistry, it provides rapid, reliable results that support timely clinical intervention and outbreak surveillance.
Genes2Me is a CE Marked molecular diagnostics company trusted by clinical laboratories across global markets. The W. Nile-Q Real-Time PCR Kit meets European conformity standards for in vitro diagnostic devices, validated to international benchmarks for accuracy, reliability, and safety.
The W. Nile-Q kit uses a multiplex one-step RT-qPCR format with TaqMan chemistry. WNV-specific RNA is detected in the FAM channel, while an endogenous internal control monitored in the HEX channel verifies RNA integrity and reaction quality in every run. A positive control template is included to validate assay performance, and a no-template control confirms reagent integrity and eliminates contamination risks. Ready-to-use reagents and a straightforward protocol minimise hands-on time and reduce the potential for procedural errors.
WNV infections are often asymptomatic or present with non-specific febrile illness, making clinical diagnosis unreliable and serological testing insufficient during the early viremic phase. Molecular detection of viral RNA provides the earliest confirmation of active infection, ahead of antibody seroconversion, and is critical for patients in whom neuroinvasive disease may develop rapidly. The dual-channel detection design with built-in internal control ensures that every negative result reflects a true absence of WNV RNA rather than a failed reaction.
Simultaneously detects WNV-specific RNA in the FAM channel and validates the run via an endogenous internal control in the HEX channel, ensuring both result accuracy and workflow reliability.
The positive control validates assay performance in every run, while the no-template control confirms reagent integrity and eliminates contamination risks.
Reliable identification of WNV RNA even in low viral load samples, enabling confident diagnosis during early or subclinical infection.
Pre-formulated reagents with a 12-month shelf life under recommended storage conditions minimise setup time, reduce procedural errors, and simplify inventory management.
Results available significantly faster than traditional serological methods, enabling clinicians to initiate timely patient management decisions
Validated on RapiCycler 96, Bio-Rad CFX96, QuantStudio 5, and LightCycler 480, supporting seamless integration into existing laboratory workflows.
| Commercial Name | Old Cat No. | New Cat No. | Pack Size |
|---|---|---|---|
| W. Nile-Q Real-Time PCR Kit | G2M706121 | 50 Tests |
Since its inception in 2016, Genes2me has been constantly striving towards setting a benchmark in the diagnostics space by introducing premium quality (Made in India) diagnostic kits which are CE-IVD, ISO-13485:2016, and ISO 9001:2015 certified, assuring our clients of unparalleled quality and compliance with international standards.
© 2025 Genes2me. All rights reserved.
